{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T22:56:27Z","timestamp":1767826587469,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ejpn-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejpn.2018.02.009","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T17:26:44Z","timestamp":1520270804000},"page":"586-594","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study"],"prefix":"10.1016","volume":"22","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler J.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2018.02.009_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/jnnp.25.3.271","article-title":"Myoclonic encephalopathy of infancy","volume":"25","author":"Kinsbourne","year":"1962","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.ejpn.2018.02.009_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1056\/NEJM196808292790907","article-title":"Opsoclonus and occult neuroblastoma","volume":"279","author":"Solomon","year":"1968","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejpn.2018.02.009_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00002826-199206000-00002","article-title":"The neurobiology of opsoclonus-myoclonus","volume":"15","author":"Pranzatelli","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib4","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0022-3476(06)80167-8","article-title":"Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma","volume":"125","author":"Koh","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.ejpn.2018.02.009_bib5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1469-8749.1995.tb11944.x","article-title":"Neurobehavioral and psychosocial functioning of children with opsoclonus-myoclonus syndrome","volume":"37","author":"Papero","year":"1995","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","article-title":"Neuroepidemiologic trends in 105 U.S. cases of pediatric opsoclonus-myoclonus","volume":"22","author":"Tate","year":"2005","journal-title":"J Pediatr Oncol Nurs"},{"issue":"5","key":"10.1016\/j.ejpn.2018.02.009_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.braindev.2015.11.007","article-title":"Trends and tenets in relapsing and progressive pediatric opsoclonus-myoclonus","volume":"38","author":"Pranzatelli","year":"2016","journal-title":"Brain Dev"},{"key":"10.1016\/j.ejpn.2018.02.009_bib8","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","article-title":"B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes","volume":"62","author":"Pranzatelli","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2018.02.009_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/00043426-200411000-00006","article-title":"Immunophenotype of blood lymphocytes in neuroblastoma-associated opsoclonus-myoclonus","volume":"26","author":"Pranzatelli","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib10","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/mds.20125","article-title":"CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity","volume":"19","author":"Pranzatelli","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.ejpn.2018.02.009_bib11","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0031-3955(05)70537-X","article-title":"Biology and treatment of neuroblastoma","volume":"44","author":"Castleberry","year":"1997","journal-title":"Pediatr Clin N Am"},{"key":"10.1016\/j.ejpn.2018.02.009_bib12","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1100\/tsw.2002.863","article-title":"High dose cyclophosphamide treatment for autoimmune disorders","volume":"2","author":"Brodsky","year":"2002","journal-title":"Sci World J"},{"issue":"1","key":"10.1016\/j.ejpn.2018.02.009_bib13","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/096120330000900106","article-title":"Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers","volume":"9","author":"Amano","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.ejpn.2018.02.009_bib14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1191\/0961203303lu1028oa","article-title":"Cyclophosphamide: new approaches for systemic lupus erythematosis","volume":"13","author":"Petri","year":"2004","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.ejpn.2018.02.009_bib15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1191\/1352458502ms790oa","article-title":"Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunological effects","volume":"8","author":"Weiner","year":"2002","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.ejpn.2018.02.009_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH","volume":"308","author":"Hauser","year":"1983","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.ejpn.2018.02.009_bib17","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1007\/s10072-009-0145-4","article-title":"Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks","volume":"30","author":"Rinaldi","year":"2009","journal-title":"Neurol Sci"},{"issue":"3","key":"10.1016\/j.ejpn.2018.02.009_bib18","first-page":"495","article-title":"Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis","volume":"50","author":"Ten Berge","year":"1982","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.ejpn.2018.02.009_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0165-5728(87)90050-6","article-title":"Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters","volume":"14","author":"Moody","year":"1987","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/clpt.1982.135","article-title":"Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide","volume":"32","author":"Egorin","year":"1982","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ejpn.2018.02.009_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejpn.2007.05.005","article-title":"Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses","volume":"12","author":"Wilken","year":"2008","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/(SICI)1096-911X(199704)28:4<284::AID-MPO7>3.0.CO;2-E","article-title":"Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the pediatric oncology group","volume":"29","author":"Russo","year":"1997","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib23","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1067\/mpd.2001.118200","article-title":"Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies","volume":"139","author":"Hayward","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.ejpn.2018.02.009_bib24","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/mpo.1138","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies\u2014a report from the child's cancer group study","volume":"36","author":"Rudnick","year":"2001","journal-title":"Med Pediatr Oncol"},{"issue":"1","key":"10.1016\/j.ejpn.2018.02.009_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2352-4642(17)30130-X","article-title":"Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomized, open-label, phase 3 trial","volume":"2","author":"de Alarcon","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"7","key":"10.1016\/j.ejpn.2018.02.009_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0883073811428816","article-title":"Active comparator-controlled, rater-blinded study of ACTH-based immunotherapies for OMS","volume":"27","author":"Tate","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib27","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0022-3476(95)70322-5","article-title":"Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G","volume":"127","author":"Petruzzi","year":"1995","journal-title":"J Pediatr"},{"key":"10.1016\/j.ejpn.2018.02.009_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1651-2227.1992.tb12248.x","article-title":"High dose iv human immunoglobulin in a case with infantile opsoclonus polymyoclonic syndrome","volume":"81","author":"Sugie","year":"1992","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.ejpn.2018.02.009_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199619010-00001","article-title":"The immunopharmacology of the opsoclonus-myoclonus syndrome","volume":"9","author":"Pranzatelli","year":"1996","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.ejpn.2018.02.009_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u2018no evidence of disease activity\u2019 in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ejpn.2018.02.009_bib31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002826-200111000-00007","article-title":"A controlled pilot study of piracetam for pediatric opsoclonus-myoclonus","volume":"24","author":"Pranzatelli","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/clin.1994.1023","article-title":"Age-related changes in human blood lymphocyte subpopulations","volume":"70","author":"Hulstaert","year":"1994","journal-title":"Clin Immun Immun"},{"key":"10.1016\/j.ejpn.2018.02.009_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3476(97)70200-2","article-title":"Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations","volume":"130","author":"Comans-Bitter","year":"1997","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.ejpn.2018.02.009_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ajcp\/100.2.111","article-title":"Reference ranges for lymphocyte subsets in pediatric patients","volume":"100","author":"Kotylo","year":"1993","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.ejpn.2018.02.009_bib35","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MPH.0b013e3181cf0726","article-title":"Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome","volume":"32","author":"Pranzatelli","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"10.1016\/j.ejpn.2018.02.009_bib36","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0883073814549581","article-title":"Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS)","volume":"30","author":"Mitchell","year":"2015","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.ejpn.2018.02.009_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.spen.2017.08.001","article-title":"Promise, progress, and pitfalls in the search for CNS biomarkers in neuroimmunological diseases: a role for CSF immunophenotyping","volume":"24","author":"Bielekova","year":"2017","journal-title":"Sem Pediatr Neurol"},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2018.02.009_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.12.014","article-title":"Key role of CXCL13\/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS","volume":"243","author":"Pranzatelli","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1742-2094-10-10","article-title":"BAFF\/APRIL system in pediatric OMS:relation to severity, neuroinflammation, and immunotherapy","volume":"10","author":"Pranzatelli","year":"2013","journal-title":"J Neuroinflamm"},{"issue":"1\u20132","key":"10.1016\/j.ejpn.2018.02.009_bib40","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2013.11.004","article-title":"CSF neurofilament light chain is increased in OMS, decreasing with immunotherapy, and other pediatric neuroinflammatory disorders","volume":"266","author":"Pranzatelli","year":"2014","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.ejpn.2018.02.009_bib41","doi-asserted-by":"crossref","first-page":"106113","DOI":"10.1007\/s10875-009-9335-3","article-title":"Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus","volume":"30","author":"Pranzatelli","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib42","unstructured":"ClinicalTrials.gov Identifier: NCT01868269. Opsoclonus myoclonus syndrome\/dancing eye syndrome (OMS\/DES) in children with and without neuroblastoma (NBpos and NBneg). Sponsor: Institut Curie."},{"key":"10.1016\/j.ejpn.2018.02.009_bib43","first-page":"1274","article-title":"Pharmacology of antineoplastic agents and multidrug resistance","volume":"vol. 2","author":"Berg","year":"2003"},{"key":"10.1016\/j.ejpn.2018.02.009_bib44","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pediatrneurol.2017.04.027","article-title":"Dexamethasone, intravenous immunoglobulin, and rituximab combination immunotherapy for pediatric opsoclonus-myoclonus syndrome","volume":"73","author":"Pranzatelli","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2018.02.009_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0009-8981(80)90212-0","article-title":"Determination\u00a0of\u00a0cyclophosphamide in urine, serum, and cerebrospinal fluid of multiple sclerosis patients by field desorption mass spectrometry","volume":"103","author":"Bahr","year":"1980","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ejpn.2018.02.009_bib46","first-page":"2113","article-title":"Cerebrospinal fluid penetration of active metabolites of cyclophosphamide and ifosfamide in rhesus monkeys","volume":"48","author":"Arndt","year":"1988","journal-title":"Cancer Res"},{"issue":"Suppl. 3","key":"10.1016\/j.ejpn.2018.02.009_bib47","first-page":"89","article-title":"Pharmacology of cyclophosphamide and its metabolites","volume":"65","author":"Colvin","year":"1981","journal-title":"Cancer Treat Rep"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037981731992X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109037981731992X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T18:55:30Z","timestamp":1635965730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109037981731992X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S109037981731992X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2018.02.009","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of low-dose cyclophosphamide, ACTH, and IVIG combination immunotherapy on neuroinflammation in pediatric-onset OMS: A retrospective pilot study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2018.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}